ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley , will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 2:25 p.m. Eastern time, in the Starlight Center Salon at The Waldorf Astoria hotel in New York City.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.
(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
SOURCE ADVENTRX Pharmaceuticals, Inc.
RELATED LINKS
http://www.adventrx.com
More by this Source
ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
Feb 28, 2013, 17:15 ET
Adventrx To Develop ANX-188 For Complications Of Arterial Disease
Feb 28, 2013, 16:01 ET
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
Feb 26, 2013, 08:00 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.